<DOC>
	<DOC>NCT00132808</DOC>
	<brief_summary>Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.</brief_summary>
	<brief_title>Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal Greater than or equal to 45 years of age Osteopenia (lumbar spine bone mineral density [BMD] Tscore between 1.0 and 2.5, and BMD Tscore &gt; 2.5 at the femoral neck) Patients with more than one Grade 1 vertebral fracture (as per Genant method; patients with one Grade 1 vertebral fracture are eligible to participate) Patients with any Grade 2 or 3 vertebral fracture (as per Genant method) Patients with 25(OH) vitamin D levels less than 15 ng/mL prior to randomization Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Postmenopausal osteoporosis</keyword>
	<keyword>osteopenia</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>Osteopenia (osteoporosis prevention)</keyword>
</DOC>